GlassScriptPhysician profile
Brian J Mihok
NPI 1164613303
$7,254.02
in general payments reported to CMS, 2019-2025
28 companies · $985 in 2025
The $985 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $767 · 2021: $1,104 · 2022: $1,392 · 2023: $978 · 2024: $1,125 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,669.79 | 2019-2025 | Clareon, Hydrus Microstent, Argos |
| Sight Sciences, INC. | $573.07 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $547.54 | 2019-2022 | |
| Abbvie INC. | $462.49 | 2022-2025 | |
| Amgen INC. | $284.23 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $250.00 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Shire North American Group INC | $245.79 | 2019 | |
| Rxsight INC | $199.85 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| New World Medical,INC. | $193.82 | 2022-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Clearpath |
| Rayner Intraocular Lenses Limited | $186.42 | 2024-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Horizon Therapeutics Plc | $172.75 | 2021-2023 | Tepezza |
| Glaukos Corporation | $169.79 | 2022-2025 | Istent Infinite |
| Novartis Pharmaceuticals Corporation | $164.19 | 2019-2023 | |
| Lensar, INC. | $157.22 | 2021 | |
| Microsurgical Technology, INC. | $152.50 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $143.00 | 2019 | |
| Ivantis, INC | $139.64 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $134.71 | 2021 | |
| Harrow Eye, LLC | $99.02 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.30 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $51.10 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $38.82 | 2021-2022 | |
| Astellas Pharma US INC | $25.00 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $22.96 | 2025 | Ryzumvi, Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $21.49 | 2024 | Xdemvy |
| Dompe US, INC. | $18.71 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $18.66 | 2023 | Flarex |
| Aerie Pharmaceuticals, INC. | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mihok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.